DENVER BUSINESS JOURNAL - A Colorado biotech that's enjoyed several months of drama said it's naming a new CEO.
Bioptix Inc. of Castle Rock used to be known as Venaxis Inc. It said that CEO Steve Lundy will be replaced by Michael Beeghley, the company's board chairman.
"Mr. Lundy's resignation was not the result of any disagreement with the company," Bioptix said in a statement.
But his last few months in office contained plenty of drama.
Read more at the Denver Business Journal: http://bit.ly/2oUJgyY
Copyright 2017 Denver Business Journal